Associations between SLCO1B1, APOE and CYP2C9 and lipid-lowering efficacy and pharmacokinetics of fluvastatin: a meta-analysis.
Pharmacogenomics
; 24(8): 475-484, 2023 06.
Article
em En
| MEDLINE
| ID: mdl-37318060
ABSTRACT
Objective:
This meta-analysis was designed to investigate the associations between SLCO1B1, APOE and CYP2C9 and the lipid-lowering effects and pharmacokinetics of fluvastatin.Methods:
Studies were searched from inception to March 2023, including three SNPs related to fluvastatin, SLCO1B1, CYP2C9 and APOE. Weighted mean differences and corresponding 95% CIs were analyzed to evaluate the associations between SNPs and outcomes.Results:
SLCO1B1 521T>C was associated with lower total cholesterol and low-density lipoprotein reduction. Patients carrying 521CC or total cholesterol had a significantly higher area under the curve than those carrying 521TT, but no significant difference existed.Conclusion:
CYP2C9 and SLCO1B1 may be associated with the efficacy and pharmacokinetics of fluvastatin.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Colesterol
/
Inibidores de Hidroximetilglutaril-CoA Redutases
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article